Sun Pharma Share Price Rises 2%; Launches LEQSELVI in U.S. After Patent Settlement with Incyte

Sun Pharmaceutical Industries Limited has announced a significant development in its ongoing efforts to expand in the U.S. dermatology and speciality treatments market.

The company has entered into a settlement and license agreement with Incyte Corporation regarding a litigation over LEQSELVI™ (deuruxolitinib), a drug used to treat severe alopecia areata.

Settlement and Licensing Agreement

As per the agreement, both parties, Sun Pharma and Incyte, have agreed to dismiss the ongoing litigation in the U.S. District Court for the District of New Jersey. They will also mutually release each other from all claims related to the case.

Under the terms of the settlement, Incyte has granted Sun a limited, non-exclusive license to use U.S. Patent No. 9,662,335 and other related patents for oral deuruxolitinib in treating non-hematology-oncology indications such as alopecia areata in the U.S. Sun will make an upfront payment to Incyte and pay ongoing royalties until the expiration of the relevant patents. The financial details of the agreement remain confidential.

LEQSELVI Launch and Clinical Significance

Following the agreement, LEQSELVI™ 8 mg tablets are now available in the U.S. for healthcare providers and patients with severe alopecia areata. The drug showed promising results in clinical trials, with nearly one-third of patients regaining almost all their hair by Week 24. Additionally, 3% of patients experienced 80% or more scalp coverage within 8 weeks, offering hope to individuals with limited treatment options.

Sun Pharma’s Financial Overview

As of July 8, 2025, Sun Pharma boasts a market capitalisation of ₹3,960 billion (US$ 46 billion). The company’s sales have shown steady year-on-year growth, rising from ₹332,331 crore in FY21 to ₹520,412 crore in FY25, marking a 9% YoY growth in the most recent fiscal year.

Sun Pharma Share Price Performance

On July 15, 2025, Sun Pharma share price opened at ₹1,705.00, up from its previous close of ₹1,682.60. At 12:04 PM, the share price of Sun Pharma was trading at ₹1,722.60, up by 2.38% on the NSE.

Also Read: Best Pharma Stocks in July 2025!

Conclusion

This settlement not only resolves legal uncertainty for Sun Pharma but also strengthens its footprint in the U.S. speciality market. With LEQSELVI’s launch, the company aims to address the unmet needs in alopecia areata treatment, potentially unlocking new growth avenues in the global dermatology segment.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.